
Rezolute (RZLT) Stock Forecast & Price Target
Rezolute (RZLT) Analyst Ratings
Bulls say
Rezolute Inc. demonstrates a promising outlook due to the substantial improvement in hypoglycemia observed with its drug candidate, ersodetug, which has proven well tolerated among participants. Additionally, insights from key opinion leader discussions indicate that up to 70% of congenital hyperinsulinism patients do not respond to standard of care treatments, highlighting a significant market opportunity for an efficacious therapy with a superior safety profile. The company's focus on addressing unmet medical needs through innovative therapies positions it favorably for revenue growth and value creation contingent upon successful product development and regulatory approvals.
Bears say
Rezolute Inc reported a net loss of $24.4 million for 4Q25, which is slightly below the consensus estimate of $25.9 million, indicating continued financial struggles. For FY25, the company is anticipated to incur a net loss of $74.4 million, which, while better than the consensus estimate of $95 million, still reflects significant ongoing financial burden. Furthermore, potential delays in regulatory approvals, exacerbated by pressures on the FDA's workforce, may hinder the company's ability to successfully bring its therapies to market, further impacting its financial outlook.
This aggregate rating is based on analysts' research of Rezolute and is not a guaranteed prediction by Public.com or investment advice.
Rezolute (RZLT) Analyst Forecast & Price Prediction
Start investing in Rezolute (RZLT)
Order type
Buy in
Order amount
Est. shares
0 shares